Health and Me

Rachel V Thomas

Bundibugyo Ebola Outbreak: WHO Identifies Experimental Treatments, Vaccines

Amid the ongoing deadly Ebola outbreak, the World Health Organization (WHO) has identified experimental treatments and vaccine candidates for the Bundibugyo strain, which currently has no approved vaccine or antiviral treatment.

The global health agency convened several expert and advisory groups and recommended prioritizing treatment of Bundibugyo cases with:

<ul><li>Mapp Biopharmaceutical's MBP134</li><li>Regeneron’s maftivimab</li><li>Gilead Sciences’ antiviral remdesivir</li></ul>

In addition, the WHO also advised evaluating combination therapy using a monoclonal antibody together with remdesivir.

The advisory groups recommended that all identified products should be used exclusively within clinical trials to generate robust data and ensure safe, ethical, and effective research.

<h2>Preventive Therapies, Vaccine Candidates</h2>

Beyond treatment, the WHO also proposed therapies for the prevention of Bundibugyo cases.

<ul><li>For post-exposure prophylaxis among contacts of confirmed and probable cases, the oral antiviral obeldesivir was identified as a priority candidate. </li></ul>

<ul><li>The expert groups also identified the single-dose rVSV Bundibugyo vaccine, being developed by the International AIDS Vaccine Initiative (IAVI), as the most promising vaccine candidate.</li></ul>Also read: <a href="https://www.healthandme.com/health-news/ebola-inside-indias-rt-pcr-tests-for-the-bundibugyo-strain-explained-article-154411961" data-type="tilCustomLink">Ebola: Inside India’s RT-PCR Tests For The Bundibugyo Strain| Explained</a>

The development of the vaccine is expected to take approximately 7–9 months before it can be assessed through clinical trials for its ability to prevent Bundibugyo disease (BDV).

<ul><li>Another vaccine candidate, ChAdOx1 Bundibugyo — being developed by Oxford University and the Serum Institute of India — could potentially become available within 2–3 months for efficacy assessment through a clinical trial. However, additional animal data are still required to support and confirm further prioritization.</li></ul>Experts noted that a single-dose approach for this candidate could be suitable for contacts of Ebola cases, while a two-dose strategy may be considered for high-risk but unexposed populations such as healthcare workers and frontline responders.

<ul><li>The experts also reviewed the potential role of Merck's Ervebo, the only licensed Ebola vaccine currently available.</li></ul>Ervebo is approved for use during outbreaks caused by the most common Ebola virus species in Africa from the Orthoebolavirus family. However, it is not licensed for the prevention of Bundibugyo disease, and evidence regarding cross-protection against other Ebola virus species remains limited and inconclusive.

The WHO stated that Ervebo should not be used outside carefully designed research settings so that its performance against Bundibugyo disease can be properly assessed.

Meanwhile, Regeneron said in a statement that supplies of maftivimab are already available in the Democratic Republic of Congo, if the WHO decides to utilize the treatment immediately or include it as part of additional studies.

Read More: <a href="https://www.healthandme.com/health-news/donald-trump-says-health-check-up-went-perfectly-article-154407790 " data-type="tilCustomLink">Donald Trump Says Health Check-Up Went 'Perfectly'</a>

Meanwhile, Russia has claimed that its scientists have developed a novel vaccine against a new Ebola strain.

According to Russian Health Minister Murashko, "the vaccine may also protect against the rare Bundibugyo strain linked to the current outbreak in the DR Congo".

It is because the "genetic similarity between this virus variant and the vaccine strain is about 60-70%," Alexander Gintsburg, scientific director of the Gamaleya National Center of Epidemiology and Microbiology, was quoted as saying GxP News.

The rare Bundibugyo strain has so far caused over 900 cases and more than 200 deaths in the Democratic Republic of the Congo and Uganda.

Health Conditions A-Z

health

bundibugyo-ebola-outbreak-who-identifies-experimental-treatments-vaccines

Bundibugyo Ebola Outbreak

Ebola Outbreak

Bundibugyo Outbreak

bundibugyo vaccine

Bundibugyo

Gilead Sciences

bundibugyo antiviral

ebola monoclonal antibody

Regeneron

india-makes-significant-progress-in-maternal-care-nutrition-and-child-immunization-nfhs-6

India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6

world-no-tobacco-day-2026-india-launches-tofei-app-to-make-campuses-tobacco-free

World No Tobacco Day 2026: India Launches ToFEI App To Make Campuses Tobacco-Free

Health News

8 Sit-Up Variations to Strengthen Your Core and Build Stability

Benefits Of Ayurvedic Health Supplement Ashwagandha

9 Anti-Inflammatory Breakfast Options You Should Try

5 Foods You Should Avoid For PCOS, Says Gynecologist

Love Sitting With Your Legs Crossed? Here’s You Should Avoid It

6 Daily Foods That Are Secretly Increasing Your Calories

9 Brain Boosters You Should Do Everyday

Hip Exercises That Will Keep You Flexible As You Age

9 Leg Exercises Office Workers’ Should Do At Home

Benefits of Having Herbal Tea Every Morning

9 Daily Habits That Boost Your Brain Power

Lower-Body Exercises That Are Game-Changers

How Drinking Apple Cider Vinegar Helps You

Aging Myths You Should Never Believe

Superfoods That Support Your Gut Health

What Happens To Your Body When You Eat Instant Noodles Every Day?

Health Issues Premature Babies Often Face

Exercises Office Workers Should Do For Their Heart Health

Reasons Why You Should Add Raw Turmeric To Your Diet

Benefits Of Drinking Milk At Night: Why You Should Do It

Food That Provides Vitamin B12 Naturally In Your Diet

Surprising Health Benefits Of Fenugreek Seeds

9 Superfoods You Should Eat For Your Brain Health

What Does Mental Health Support Look Like At Work?

Long Stretches You Should Do To Unwind From Your Day

Colon Cancer In Young Adults: Early Symptoms You Should Know

Health Benefits Of Eating Dry Fruits Everyday

Are You At Risk For Fried Rice Syndrome?

These Tests Reveal How Well You Are Aging

Lower-Back Exercises You Should Do After A Long-Day's Work

Children’s Diet – What Kids Need To Eat For Immunity Building

Common Diabetes Myths That Could Hurt Your Health

Love Spicy Food? Here’s How It Affects Your Health

Superfood List: Veggies And Fruits You Must Have For Immunity

Foods People With IBS Should Avoid

Exercises To Improve Digestion

Easy Work Lunches You Can Make In The Morning

Hunger Vs Craving: Difference Explained In 60 seconds

These Things Can Cause Your Heart To Age Faster

High Carb Foods That Are Actually Healthy

Amid the ongoing deadly Ebola outbreak, the World Health Organization (WHO) has identified experimental treatments and vaccine candidates for the Bundibugyo strain, which currently has no approved vaccine or antiviral treatment.The global health agency convened several expert and advisory groups and recommended prioritizing treatment of Bundibugyo cases with:Mapp Biopharmaceutical's MBP134Regeneron’s maftivimabGilead Sciences’ antiviral remdesivirIn addition, the WHO also advised evaluating combination therapy using a monoclonal antibody together with remdesivir.The advisory groups recommended that all identified products should be used exclusively within clinical trials to generate robust data and ensure safe, ethical, and effective research.Preventive Therapies, Vaccine CandidatesBeyond treatment, the WHO also proposed therapies for the prevention of Bundibugyo cases.For post-exposure prophylaxis among contacts of confirmed and probable cases, the oral antiviral obeldesivir was identified as a priority candidate. The expert groups also identified the single-dose rVSV Bundibugyo vaccine, being developed by the International AIDS Vaccine Initiative (IAVI), as the most promising vaccine candidate.Also read: Ebola: Inside India’s RT-PCR Tests For The Bundibugyo Strain| ExplainedThe development of the vaccine is expected to take approximately 7–9 months before it can be assessed through clinical trials for its ability to prevent Bundibugyo disease (BDV).Another vaccine candidate, ChAdOx1 Bundibugyo — being developed by Oxford University and the Serum Institute of India — could potentially become available within 2–3 months for efficacy assessment through a clinical trial. However, additional animal data are still required to support and confirm further prioritization.Experts noted that a single-dose approach for this candidate could be suitable for contacts of Ebola cases, while a two-dose strategy may be considered for high-risk but unexposed populations such as healthcare workers and frontline responders.The experts also reviewed the potential role of Merck's Ervebo, the only licensed Ebola vaccine currently available.Ervebo is approved for use during outbreaks caused by the most common Ebola virus species in Africa from the Orthoebolavirus family. However, it is not licensed for the prevention of Bundibugyo disease, and evidence regarding cross-protection against other Ebola virus species remains limited and inconclusive.The WHO stated that Ervebo should not be used outside carefully designed research settings so that its performance against Bundibugyo disease can be properly assessed.Meanwhile, Regeneron said in a statement that supplies of maftivimab are already available in the Democratic Republic of Congo, if the WHO decides to utilize the treatment immediately or include it as part of additional studies.Read More: Donald Trump Says Health Check-Up Went 'Perfectly'Russian Vaccine For New StrainMeanwhile, Russia has claimed that its scientists have developed a novel vaccine against a new Ebola strain.According to Russian Health Minister Murashko, "the vaccine may also protect against the rare Bundibugyo strain linked to the current outbreak in the DR Congo".It is because the "genetic similarity between this virus variant and the vaccine strain is about 60-70%," Alexander Gintsburg, scientific director of the Gamaleya National Center of Epidemiology and Microbiology, was quoted as saying GxP News.The rare Bundibugyo strain has so far caused over 900 cases and more than 200 deaths in the Democratic Republic of the Congo and Uganda.

bundibugyo ebola outbreak: who identifies experimental treatments, vaccines

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Bundibugyo Ebola Outbreak: WHO Identifies Experimental Treatments, Vaccines

India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6

World No Tobacco Day 2026: India Launches ToFEI App To Make Campuses Tobacco-Free

Global Temperatures Likely To Stay Near Record Levels For Next Five Years: WMO

Health Conditions A-Z

India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6

Bundibugyo Ebola Outbreak: WHO Identifies Experimental Treatments, Vaccines

World No Tobacco Day 2026: India Launches ToFEI App To Make Campuses Tobacco-Free